Intravenous immunoglobulin given to lymphoma patients with recurrent haemolytic transfusion reactions after transfusion of compatible blood.
Accelerated destruction of red cells after transfusion of compatible blood has been reported in both sickle cell disease (SCD) and non-SCD patients. We report three patients with lymphoma, all of whom had recurrent haemolytic transfusion reactions after receiving compatible red cell units. The direct antiglobulin test (DAT) was negative and there were no detectable red cell alloantibodies in either pre-transfusion or post-transfusion samples. As there was no evidence of red cell antibody-mediated haemolysis and response to oral steroids, a trial of intravenous immunoglobulin (IVIg) was given. Immediate cessation of haemolysis with sustained haemoglobin level was achieved in all cases. The response to IVIg in these cases suggests that IVIg should be tried when recurrent non-antibody mediated haemolytic transfusion reactions occur in patients with a lymphoid malignancy.
Win
N
N
Red Cell Immunohaematology, National Blood Service-Tooting Centre, 75 Cranmer Terr, London, ORB, UK. nay.win@nbs.nhs.uk
Madan
B
B
Gale
R
R
Matthey
F
F
D000368:Aged; D000369:Aged, 80 and over; D001803:Blood Transfusion; D005260:Female; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D008223:Lymphoma / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D013256:Steroids / Q000008:administration & dosage*; D065227:Transfusion Reaction
D016756:Immunoglobulins, Intravenous; D013256:Steroids